Physiogenex to present at the KinMet 2010 & ATVB 2010 annual conference in San Francisco, April 7th-10th, 2010 -Physiogenex will present the effects of CETP inhibitor torcetrapib on macrophage-to-feces reverse cholesterol transport in the obese insulin resistant CETP-apoB100 transgenic mice.Physiogenex will present the effects of CETP inhibitor torcetrapib on macrophage-to-feces reverse cholesterol transport in the obese insulin resistant CETP-apoB100 transgenic mice.
The recent development of this animal model enabled to demonstrate that a diet induced obesity/insulin resistance in CETP-apoB100 transgenic mice severely impairs macrophage-to-feces reverse cholesterol transport and that torcetrapib has the potential to stimulate this anti-atherogenic process... Physiogenex's Press Release -
About Physiogenex
Physiogenex is a renowned CRO biotechnology leader specializing in metabolic and cardiovascular diseases. In this focused niche market we offer dedicated in-house and R&D customized solutions designed to help our partners optimize their drug discovery and preclinical development on a fee-for-service basis.
Physiogenex pioneers the development of radiotracer-based kinetic methods and predictive animal nutritional models, thus providing our partners with the pertinent and reliable discovery and preclinical data they need for successful strategic decision-making. Physiogenex has rapidly achieved global player status by virtue of its unique expertise covering complex metabolic disorders associated with diabetes, obesity, lipid disorders, hypertension and cardiovascular diseases... Physiogenex - Company overview -
